| (210) | Number of the EPO application | 15832772 |
| (220) | Filing date of the EPO application | 2015.12.29 |
| (80) | EPO patent specification publication (B) | EPB nr. 45/2019, 2019.11.06 |
| (110) | EPO patent number | 3240791 |
| (21) | Number of the application | e 2017 0254 |
| (71) | Name(s) of applicant(s), code of the country | Forma Therapeutics, Inc., US; |
| (72) | Name(s) of inventor(s), code of the country | IOANNIDIS Stephanos, US;
TALBOT Adam Charles, US;
FOLLOWS Bruce, US;
BUCKMELTER Alexandre Joseph, US;
WANG Minghua, US;
CAMPBELL Ann-Marie, US;
SCHMIDT Darby Rye, US;
GUERIN David Joseph, US;
CARAVELLA Justin A., US;
DIEBOLD R. Bruce, US;
ERICSSON Anna, US;
LANCIA David R. Jr., US; |
| (73) | Name(s) of owner(s), code of the country | FORMA Therapeutics Inc., US; |
| (54) | Title of the invention | PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS |
| (13) | Kind-of-document code | A1 |
| (51) | International Patent Classification | C07D 487/04 (2006.01.01); A61K 31/519 (2006.01.01) |
| (19) | Country | US |
| (41) | Date of publication of the application | 2018.01.31 |
| (30) | Priority | 201462098141 P, 2014.12.30, US |
| (86) | International application | PCT/US2015/067831, 2015.12.29 |
| (87) | International publication | WO 2016/109515, 2016.07.07 |